|
|
| WHO Expert Committee on Drug Dependence |
|
|
|
|
| Thirty-fifth Report |
| Technical Report Series, No 973 |
| World Health Organization |
|
|
ISBN-13
9789241209731
|
ISBN-10
9241209739
|
|
|
Order Number
11000973
|
|
|
Price
CHF
14.00
/
US$
16.80
|
Developing countries:
CHF
9.80
|
|
|
English
2012
32
pages
|
|
|
|
|
|
|
|
| Summary |
This report presents the recommendations of a WHO Expert
Committee responsible for reviewing information on psychoactive
substances to assess the need for their international control.
The report contains a summary of the Committee's evaluations
of y-hydroxybutyric acid (GHB) and ketamine. GHB was
recommended to be rescheduled from Schedule IV to
Schedule II of the Convention on Psychotropic Substances.
The report also discusses the nine substances that were prereviewed: dextromethorphan, tapentadol, N-benzylpiperazine
(BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP),
1-(3-chlorophenyl)piperazine (mCPP), 1-(4-methoxyphenyl)
piperazine (MeOPP), 1-(3,4-methylenedioxybenzyl)piperazine
(MDBP), y-butyrolactone (GBL), and 1,4-butanediol (1,4-BD).
Of these, tapentadol, BZP, GBL and 1,4-BD were recommended
for critical review. Issues identified for consideration at future
Expert Committee meetings are also listed.
Furthermore, the report discusses the use of terms, the use
of pharmacovigilance data for the assessment of abuse and
dependence potential, balancing medical availability and
prevention of abuse of medicines manufactured from controlled
substances, and improving the process for substance evaluation. |
|
|
|
|
|
|
